Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.34 |
| ▸ | WNT1 | P04628 | 7/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | CLK3 | P49761 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7877795 | 0.90 | DYRK1A (0.35) | DYRK1AWNT1CLK2CLK3SLC6A4 | |
| SCHEMBL7882232 | 0.90 | SCN9A (0.38) | SCN9A | |
| SCHEMBL7880758 | 0.89 | SCN9A (0.38) | SCN9AMGLL | |
| SCHEMBL7879862 | 0.89 | HRH3 (0.38) | SCN9A | |
| SCHEMBL7873699 | 0.88 | SCN9A (0.38) | SCN9AMGLL | |
| SCHEMBL7884304 | 0.88 | SUCNR1 (0.32) | — | |
| SCHEMBL7873809 | 0.87 | SLC6A4 (0.35) | SCN9ASLC6A4 | |
| SCHEMBL7881197 | 0.85 | DYRK1A (0.34) | DYRK1AWNT1SCN9ACLK2CLK3 | |
| SCHEMBL7879496 | 0.85 | SCN9A (0.35) | DYRK1AWNT1SCN9ASLC6A4 | |
| SCHEMBL7881379 | 0.85 | TLR7 (0.36) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |